Selenoether Compounds for Type II Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type II diabetes and related disorders, such as hyperglycemia and obesity, often require combinations of selenoorganic compounds, where individual compounds like 5′-Methylselenoadenosine and Se-Adenosyl-L-homocysteine show limited efficacy when used alone, whereas in combination they can effectively reduce hepatic glucose output and improve glucose tolerance.
Innovation Solution
Development of new selenium-containing compounds with structural relationships to 5′-Methylselenoadenosine and Se-Adenosyl-L-homocysteine that exhibit potent activity alone, capable of reducing hepatic glucose output, improving glucose tolerance, and enhancing gluconeogenesis, which can be used in compositions for treating type II diabetes and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If individual selenoorganic compounds (5′-Methylselenoadenosine or Se-Adenosyl-L-homocysteine) are used alone, then the treatment regimen is simpler, but the efficacy in reducing hepatic glucose output and improving glucose tolerance is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of selenoorganic compounds - specifically changing the selenium-containing group from compounds of formulas I and II to a selenoether group with the structure -Se-R where R is a C1-C6 alkyl group. This structural parameter change enables the compound to achieve potent activity alone, resolving the contradiction between treatment simplicity and therapeutic efficacy.
2Reliability
If combinations of selenoorganic compounds are used, then the therapeutic efficacy is improved, but the treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the key therapeutic component by developing a single selenoorganic compound with a specific selenoether structure that embodies the essential therapeutic properties previously requiring combination therapy. This extraction principle allows the compound to function effectively as a monotherapy, reducing treatment complexity while maintaining efficacy.
3Ease of manufacture
If existing selenoorganic compounds are used, then the treatment approach is established, but the bioactivity is insufficient compared to new compounds
Solution Approach 1:
The patent changes the chemical parameter of the selenium-containing group from existing structures to a selenoether group (-Se-R where R is C1-C6 alkyl). This parameter change results in compounds with enhanced bioactivity that is comparable to or exceeds the CDE combination, while maintaining manufacturability through established pharmaceutical processes.
Data Source
AI summary
The present disclosure provides compounds of formulas (1)-(3), and compositions and methods of use thereof. The present disclosure also provides methods of preparing a provided compound and composition, and methods of characterizing a provided compound and composition.